Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors

apnews | April 23, 2019

Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the addition of Richard U. DeSchutter, Michael A. Friedman, M.D., and Stephen Rubino, Ph.D., to its board of directors. “Richard DeSchutter, Michael Friedman and Stephen Rubino each have undertaken careers marked by tremendous achievement, so we are thrilled to gain access to their deep experience and intellect while in the midst of an exciting and pivotal time period for Sermonix,” said Anthony H. Wild, Ph.D., Sermonix non-executive chairman of the board. “The new board members’ knowledge will help us draw closer to bringing lasofoxifene to metastatic breast cancer patients who are in need of new endocrine therapies that are both effective and well tolerated.” Lasofoxifene, Sermonix’s lead investigational drug, is a nonsteroidal selective estrogen receptor modulator (SERM) that could potentially hold promise as a precision medicine for patients who have acquired endocrine resistance and ESR1 mutations, a common mutation in the metastatic setting and an area of high unmet medical need. Sermonix is currently enrolling the Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) study, assessing the activity of oral lasofoxifene versus intramuscular fulvestrant in advanced breast cancer with ESR1 mutations

Spotlight

In practice, of course, things are more complicated. Effective translation necessitates a nuanced understanding of (at least) two languages and cultures, both source and target. It requires an understanding of the original content’s goals. It mandates a fluency in tone and subtext as well as vocabulary and grammar. In short, it requires a highly competent person to effect resonance. In theory, companies could (and some do) perform translation and localization work in-house. But the reason so many choose not to is because a language service provider (LSP) like Lionbridge can help simplify processes (and, in the long run, reduce costs) when translation and localization get really complicated.

Spotlight

In practice, of course, things are more complicated. Effective translation necessitates a nuanced understanding of (at least) two languages and cultures, both source and target. It requires an understanding of the original content’s goals. It mandates a fluency in tone and subtext as well as vocabulary and grammar. In short, it requires a highly competent person to effect resonance. In theory, companies could (and some do) perform translation and localization work in-house. But the reason so many choose not to is because a language service provider (LSP) like Lionbridge can help simplify processes (and, in the long run, reduce costs) when translation and localization get really complicated.

Related News

MEDICAL

HealthMyne's Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses

HealthMyne | September 22, 2021

HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma in chest CT scans. Researchers analyzed radiomic biomarkers to predict Overall Survival (OS) and Progression Free Survival (PFS) time. To perform the study, researchers selected 74 patients with histologically confirmed lung cancer who underwent immunotherapy and compared them with 50 patients with histologically confirmed lung adenocarcinoma who underwent chemotherapy alone or in combination with targeted therapy. Researchers segmented each patient's lesion leveraging HealthMyne's advanced imaging analytics solution to extract 573 radiometric metrics from the cohort images to predict OS and PFS time. Researchers found that 19 radiomic features were significant for predicting OS and 108 radiomic features for predicting PFS time. Researchers concluded that the study demonstrated the relationship between radiomics and immunotherapeutic response and that specific radiomic features can be used to select patients with lung adenocarcinoma who would benefit from immunotherapy. To maximize the value of research and development investments, drug developers need an accurate and efficient means of selecting and stratifying patients for clinical studies. Numerous examples of peer-reviewed research have shown that radiomics and precision image analysis identifies biomarkers that drive greater personalization of treatment and provides new insights for better decisions. At HealthMyne, we strive to develop innovative radiomic solutions that contribute to the advancement of this critical body of evidence. - Rose Higgins, CEO, HealthMyne. About HealthMyne HealthMyne® is a pioneer in applied radiomics, the cutting-edge field of extracting novel data and biomarkers from medical images. Our FDA-approved and CE marked, AI-enabled solutions allow organizations to easily access and translate groundbreaking radiomic insights into use in research, clinical outcomes, and treatment pathways. By leveraging radiomics, our clients and partners can accelerate the development and delivery of the best possible treatments. HealthMyne's approach is based upon the premise that every cancer patient's story begins with an image. We believe that unleashing the hidden power of imaging data and radiomics will revolutionize personalized care -- ensuring the right treatment every time. Our mission is to advance precision health initiatives through accessible and translatable radiomic data.

Read More

RESEARCH

TurtleTree Launches New Research and Development Facility in Greater Sacramento

TurtleTree | October 04, 2021

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk ingredients like lactoferrin. This marks a significant stride towards the production of consumer-ready milk and dairy, reaffirming TurtleTree's status as a leading player in the field of sustainable nutrition. In addition to improving these capabilities, the establishment of this groundbreaking facility will also further TurtleTree's mission of uplifting the world beyond the creation of sustainable food. To adequately staff the facility, the company will create approximately 40 new tech-related jobs in and around Greater Sacramento. These will span diverse fields from food science to engineering, yielding fresh opportunities for seasoned professionals and fresh graduates alike. Referencing this positive impact, TurtleTree's CEO and co-founder, Fengru Lin, stated: "Establishing this R&D facility in Greater Sacramento marks the first step towards bringing our unique products from development to market—one that we're very glad will help unlock new opportunities within the local community. We're eagerly looking forward to working with the brilliant talent in the area and building a future generation of nutrition that we can all enjoy for decades to come." Echoing similar sentiments, various West Sacramento representatives have also offered their support for the new facility. President and CEO of the Greater Sacramento Economic Council, Barry Broome, stated: "We want to congratulate TurtleTree for locating their R&D and manufacturing facility in West Sacramento. This move signals market validation of why Greater Sacramento is world-class in biotech, specifically alternative proteins research." West Sacramento is honored to have been chosen by TurtleTree as the location for their much-anticipated research facility. The city looks forward to assisting the TurtleTree leadership to achieve their goals, with respect to the facility, through an accelerated occupancy permit process, TurtleTree is making significant contributions to a sustainable, global food supply and is also creating opportunities to prepare future generations to continue this important scientific work through our student internship program, which will be of great benefit to the city's youth. -West Sacramento mayor, Martha Guerrero Moving forward, TurtleTree remains committed to its role in developing the food and agriculture ecosystem in Northern California. Aside from functioning as a research hub, the R&D facility will also serve as an integral touchpoint for TurtleTree to connect and collaborate with educational institutions, research-focused partners, strategic partners, future customers, and investors. About TurtleTree TurtleTree is a biotech company that's using cell-based technologies to create sustainable food and dairy. In spite of this, we earnestly believe that what we do extends beyond the dining table and into the heart of humanity. At our core, we seek to uplift the world by providing a new generation of nutrition that's better for the planet, better for the animals, and better for people everywhere. About the Greater Sacramento Economic Council (GSEC) The Greater Sacramento Economic Council is the catalyst for innovative growth strategies in the Capital Region of California. The organization spearheads community-led direction to retain, attract, grow, and scale tradable sectors, develop advanced industries, and create jobs and investment throughout a six-county region. Greater Sacramento represents a collaboration between local and state governments, market leaders, influencers, and stakeholders, with the sole mission of driving inclusive economic growth. The Greater Sacramento region was founded on discovery, built on leadership, and fueled by innovation. About the City of West Sacramento West Sacramento is located minutes from the state capital, midway between San Francisco and Lake Tahoe, in the heart of California's Great Central Valley. West Sacramento has abundant land, high-quality water, and nearby agricultural production combined with market access and proximity to the world-renowned food and agricultural research of U.C. Davis. Over 60 companies in food and ag-tech research, production, and distribution have established West Sacramento's Global Food Industry Hub, including Origin Materials, TOMRA Sorting Solutions, NuSeed Americas, Nor-Cal Beverage, Bayer Crop Science, and Nippon Shokken U.S.A.

Read More

CELL AND GENE THERAPY

Thermo Fisher Scientific Announces its Complete Acquisition of Mesa Biotech

Thermo Fisher Scientific | March 01, 2021

Thermo Fisher Scientific Inc. (NYSE: TMO), the world chief in serving science, today reported it has finished its recently declared obtaining of Mesa Biotech, Inc., a secretly held purpose of-care sub-atomic analytic organization. Plateau Biotech has built up the Accula System, a moderate, simple to-utilize, purpose of-care PCR-based testing stage for irresistible infection conclusion. The stage empowers fast, exceptionally precise testing at doctor workplaces, drug stores and different settings, giving outcomes quickly. Past COVID-19 testing, Mesa Biotech's current stage incorporates tests for influenza, respiratory syncytial infection (RSV), and Strep A. "The Accula System complements our existing offerings and immediately provides our clinical customers with more options and flexibility for COVID-19 testing. And, as the point-of-care diagnostic market expands globally, we're well-positioned to deliver a broader menu of tests to meet increasing demand," Stevenson continued. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Read More